AB0658 Influence of Known Risk Factors on Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Long-Term Treatment with TNF Inhibitors: Results from The Glas Cohort

BackgroundIn ankylosing spondylitis (AS), the most important prognostic factor for spinal radiographic progression is the presence of syndesmophytes at study entry. In addition, male gender, older age, longer symptom duration, smoking, HLA-B27 positivity, and increased inflammatory markers were foun...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2016-06, Vol.75 (Suppl 2), p.1129-1130
Hauptverfasser: Maas, F., Arends, S., Wink, F.R., van der Veer, E., Bos, R., Bootsma, H., Brouwer, E., Spoorenberg, A.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1130
container_issue Suppl 2
container_start_page 1129
container_title Annals of the rheumatic diseases
container_volume 75
creator Maas, F.
Arends, S.
Wink, F.R.
van der Veer, E.
Bos, R.
Bootsma, H.
Brouwer, E.
Spoorenberg, A.
description BackgroundIn ankylosing spondylitis (AS), the most important prognostic factor for spinal radiographic progression is the presence of syndesmophytes at study entry. In addition, male gender, older age, longer symptom duration, smoking, HLA-B27 positivity, and increased inflammatory markers were found to be associated with radiographic progression in AS.1ObjectivesTo investigate the influence of known risk factors on spinal radiographic progression in AS patients receiving long-term treatment with TNF inhibitors.MethodsConsecutive patients from the GLAS cohort receiving TNF inhibitors with baseline and biannual spinal radiographs untill 6 years of follow-up were included. Radiographs were scored in chronological time order by two independent readers according to the mSASSS. Single linear imputation of radiographic data was used in case patients had missing data at one or more intermediate follow-up visits. The influence of the earlier mentioned risk factors for radiographic progression was investigated using univariable and multivariable generalized estimating equations (GEE). Subsequently, radiographic progression was modeled with different time functions (linear and non-linear) to provide the best fit for the data in patients with and without risk factors. A time function with p≤0.05 contributed significantly to the model and the estimated mean progression rates of the 2-year time intervals were calculated.ResultsEighty patients were included; 70% were male, 78% HLA-B27+, mean age was 41±10 years, median symptom duration 14 (IQR: 8–24) years, mean BASDAI 6.0±1.7, mean ASDAS 3.8±0.8, and mean mSASSS 8.7±13.3.During 6 years of follow-up, mean progression was 4.2±4.8 mSASSS units. GEE revealed that baseline syndesmophytes, gender, age, and symptom duration were significantly associated with radiographic damage over time. No significant associations were found for smoking, HLA-B27 status, and elevated CRP levels. The presence of baseline syndesmophytes was the only independent predictor for progression.Baseline mSASSS was highest in AS patients with baseline syndesmophytes, male gender, age ≥40 years, and symptom duration ≥10 years. In these patients, mSASSS progression followed a non-linear course showing a reduction in estimated progression rates over time (Table 1). Most patients with syndesmophytes also had one or more other risk factors (e.g. male gender and symptom duration ≥10 years). A linear course with low estimated progression rates was found in pa
doi_str_mv 10.1136/annrheumdis-2016-eular.3912
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1901859654</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322514469</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1274-9d02a91036b80d78332431de9a30cc0ed20533ad5d97fa2d2999eb4993eb51bf3</originalsourceid><addsrcrecordid>eNqVkU9P2zAYhy00pHWM72CJc5gdJ24Mp1KtrFq1odKdLSd-07gkdrETUG-77Gvtw_BJ5tAduHLyn9_veS35QeiCkktKGf-irPUNDJ02IUkJ5QkMrfKXTND0BE1oxot4zckHNCGEsCQTfPoRfQphF4-koMUE_Z3dEJ4XL7__LG3dDmArwK7G3617tnhtwgNeqKp3PmBn8f3eWNXitdLGbb3aN6bCdz5uIQQTc2PxzD4cWheM3ca2s_rQmt4EfKd6A7YPeA0VmKcxXjm7TTbgO7zxoPouxvjZ9A3e_FjgpW1MacZ3ryIShjaitXex2wC-bVXAc9c4339Gp7VqA5z_X8_Qr8XXzfxbsvp5u5zPVklJ02mWCE1SJShhvCyInhaMpRmjGoRipKoI6JTkjCmdazGtVapTIQSUmRAMypyWNTtDF8e5e-8eBwi93LnBx88IkgpCi1zwPIut62Or8i4ED7Xce9Mpf5CUyFGYfCNMjsLkqzA5Cos0P9Jlt3sX-A8dnqV7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901859654</pqid></control><display><type>article</type><title>AB0658 Influence of Known Risk Factors on Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Long-Term Treatment with TNF Inhibitors: Results from The Glas Cohort</title><source>BMJ Journals - NESLi2</source><creator>Maas, F. ; Arends, S. ; Wink, F.R. ; van der Veer, E. ; Bos, R. ; Bootsma, H. ; Brouwer, E. ; Spoorenberg, A.</creator><creatorcontrib>Maas, F. ; Arends, S. ; Wink, F.R. ; van der Veer, E. ; Bos, R. ; Bootsma, H. ; Brouwer, E. ; Spoorenberg, A.</creatorcontrib><description>BackgroundIn ankylosing spondylitis (AS), the most important prognostic factor for spinal radiographic progression is the presence of syndesmophytes at study entry. In addition, male gender, older age, longer symptom duration, smoking, HLA-B27 positivity, and increased inflammatory markers were found to be associated with radiographic progression in AS.1ObjectivesTo investigate the influence of known risk factors on spinal radiographic progression in AS patients receiving long-term treatment with TNF inhibitors.MethodsConsecutive patients from the GLAS cohort receiving TNF inhibitors with baseline and biannual spinal radiographs untill 6 years of follow-up were included. Radiographs were scored in chronological time order by two independent readers according to the mSASSS. Single linear imputation of radiographic data was used in case patients had missing data at one or more intermediate follow-up visits. The influence of the earlier mentioned risk factors for radiographic progression was investigated using univariable and multivariable generalized estimating equations (GEE). Subsequently, radiographic progression was modeled with different time functions (linear and non-linear) to provide the best fit for the data in patients with and without risk factors. A time function with p≤0.05 contributed significantly to the model and the estimated mean progression rates of the 2-year time intervals were calculated.ResultsEighty patients were included; 70% were male, 78% HLA-B27+, mean age was 41±10 years, median symptom duration 14 (IQR: 8–24) years, mean BASDAI 6.0±1.7, mean ASDAS 3.8±0.8, and mean mSASSS 8.7±13.3.During 6 years of follow-up, mean progression was 4.2±4.8 mSASSS units. GEE revealed that baseline syndesmophytes, gender, age, and symptom duration were significantly associated with radiographic damage over time. No significant associations were found for smoking, HLA-B27 status, and elevated CRP levels. The presence of baseline syndesmophytes was the only independent predictor for progression.Baseline mSASSS was highest in AS patients with baseline syndesmophytes, male gender, age ≥40 years, and symptom duration ≥10 years. In these patients, mSASSS progression followed a non-linear course showing a reduction in estimated progression rates over time (Table 1). Most patients with syndesmophytes also had one or more other risk factors (e.g. male gender and symptom duration ≥10 years). A linear course with low estimated progression rates was found in patients without these risk factors (Table 1).ConclusionsIn our cohort of AS patients receiving long-term treatment with TNF inhibitors in daily clinical practice, patients with known risk factors for radiographic progression (especially the presence of baseline syndesmophytes) showed the highest radiographic damage scores at baseline and the highest but reducing radiographic progression over time. In contrast, patients without these risk factors showed less baseline damage and low linear progression rates.ReferencesArends S, et al. Curr Opin Rheumatol. 2014;26:259–68.AcknowledgementThe GLAS cohort was supported by an unrestricted grant from Pfizer. Pfizer had no role in the design, conduct, interpretation, or publication of this study.Disclosure of InterestF. Maas: None declared, S. Arends Grant/research support from: Pfizer, F. Wink Consultant for: Abbvie, E. van der Veer: None declared, R. Bos Grant/research support from: Pfizer, H. Bootsma: None declared, E. Brouwer Grant/research support from: Pfizer, A. Spoorenberg Grant/research support from: Abbvie, Pfizer, UCB, Consultant for: Abbvie, Pfizer, MSD, UCB, Novartis</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2016-eular.3912</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><ispartof>Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.1129-1130</ispartof><rights>2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2016 (c) 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/75/Suppl_2/1129.2.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/75/Suppl_2/1129.2.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77343,77374</link.rule.ids></links><search><creatorcontrib>Maas, F.</creatorcontrib><creatorcontrib>Arends, S.</creatorcontrib><creatorcontrib>Wink, F.R.</creatorcontrib><creatorcontrib>van der Veer, E.</creatorcontrib><creatorcontrib>Bos, R.</creatorcontrib><creatorcontrib>Bootsma, H.</creatorcontrib><creatorcontrib>Brouwer, E.</creatorcontrib><creatorcontrib>Spoorenberg, A.</creatorcontrib><title>AB0658 Influence of Known Risk Factors on Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Long-Term Treatment with TNF Inhibitors: Results from The Glas Cohort</title><title>Annals of the rheumatic diseases</title><description>BackgroundIn ankylosing spondylitis (AS), the most important prognostic factor for spinal radiographic progression is the presence of syndesmophytes at study entry. In addition, male gender, older age, longer symptom duration, smoking, HLA-B27 positivity, and increased inflammatory markers were found to be associated with radiographic progression in AS.1ObjectivesTo investigate the influence of known risk factors on spinal radiographic progression in AS patients receiving long-term treatment with TNF inhibitors.MethodsConsecutive patients from the GLAS cohort receiving TNF inhibitors with baseline and biannual spinal radiographs untill 6 years of follow-up were included. Radiographs were scored in chronological time order by two independent readers according to the mSASSS. Single linear imputation of radiographic data was used in case patients had missing data at one or more intermediate follow-up visits. The influence of the earlier mentioned risk factors for radiographic progression was investigated using univariable and multivariable generalized estimating equations (GEE). Subsequently, radiographic progression was modeled with different time functions (linear and non-linear) to provide the best fit for the data in patients with and without risk factors. A time function with p≤0.05 contributed significantly to the model and the estimated mean progression rates of the 2-year time intervals were calculated.ResultsEighty patients were included; 70% were male, 78% HLA-B27+, mean age was 41±10 years, median symptom duration 14 (IQR: 8–24) years, mean BASDAI 6.0±1.7, mean ASDAS 3.8±0.8, and mean mSASSS 8.7±13.3.During 6 years of follow-up, mean progression was 4.2±4.8 mSASSS units. GEE revealed that baseline syndesmophytes, gender, age, and symptom duration were significantly associated with radiographic damage over time. No significant associations were found for smoking, HLA-B27 status, and elevated CRP levels. The presence of baseline syndesmophytes was the only independent predictor for progression.Baseline mSASSS was highest in AS patients with baseline syndesmophytes, male gender, age ≥40 years, and symptom duration ≥10 years. In these patients, mSASSS progression followed a non-linear course showing a reduction in estimated progression rates over time (Table 1). Most patients with syndesmophytes also had one or more other risk factors (e.g. male gender and symptom duration ≥10 years). A linear course with low estimated progression rates was found in patients without these risk factors (Table 1).ConclusionsIn our cohort of AS patients receiving long-term treatment with TNF inhibitors in daily clinical practice, patients with known risk factors for radiographic progression (especially the presence of baseline syndesmophytes) showed the highest radiographic damage scores at baseline and the highest but reducing radiographic progression over time. In contrast, patients without these risk factors showed less baseline damage and low linear progression rates.ReferencesArends S, et al. Curr Opin Rheumatol. 2014;26:259–68.AcknowledgementThe GLAS cohort was supported by an unrestricted grant from Pfizer. Pfizer had no role in the design, conduct, interpretation, or publication of this study.Disclosure of InterestF. Maas: None declared, S. Arends Grant/research support from: Pfizer, F. Wink Consultant for: Abbvie, E. van der Veer: None declared, R. Bos Grant/research support from: Pfizer, H. Bootsma: None declared, E. Brouwer Grant/research support from: Pfizer, A. Spoorenberg Grant/research support from: Abbvie, Pfizer, UCB, Consultant for: Abbvie, Pfizer, MSD, UCB, Novartis</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVkU9P2zAYhy00pHWM72CJc5gdJ24Mp1KtrFq1odKdLSd-07gkdrETUG-77Gvtw_BJ5tAduHLyn9_veS35QeiCkktKGf-irPUNDJ02IUkJ5QkMrfKXTND0BE1oxot4zckHNCGEsCQTfPoRfQphF4-koMUE_Z3dEJ4XL7__LG3dDmArwK7G3617tnhtwgNeqKp3PmBn8f3eWNXitdLGbb3aN6bCdz5uIQQTc2PxzD4cWheM3ca2s_rQmt4EfKd6A7YPeA0VmKcxXjm7TTbgO7zxoPouxvjZ9A3e_FjgpW1MacZ3ryIShjaitXex2wC-bVXAc9c4339Gp7VqA5z_X8_Qr8XXzfxbsvp5u5zPVklJ02mWCE1SJShhvCyInhaMpRmjGoRipKoI6JTkjCmdazGtVapTIQSUmRAMypyWNTtDF8e5e-8eBwi93LnBx88IkgpCi1zwPIut62Or8i4ED7Xce9Mpf5CUyFGYfCNMjsLkqzA5Cos0P9Jlt3sX-A8dnqV7</recordid><startdate>201606</startdate><enddate>201606</enddate><creator>Maas, F.</creator><creator>Arends, S.</creator><creator>Wink, F.R.</creator><creator>van der Veer, E.</creator><creator>Bos, R.</creator><creator>Bootsma, H.</creator><creator>Brouwer, E.</creator><creator>Spoorenberg, A.</creator><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>201606</creationdate><title>AB0658 Influence of Known Risk Factors on Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Long-Term Treatment with TNF Inhibitors: Results from The Glas Cohort</title><author>Maas, F. ; Arends, S. ; Wink, F.R. ; van der Veer, E. ; Bos, R. ; Bootsma, H. ; Brouwer, E. ; Spoorenberg, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1274-9d02a91036b80d78332431de9a30cc0ed20533ad5d97fa2d2999eb4993eb51bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maas, F.</creatorcontrib><creatorcontrib>Arends, S.</creatorcontrib><creatorcontrib>Wink, F.R.</creatorcontrib><creatorcontrib>van der Veer, E.</creatorcontrib><creatorcontrib>Bos, R.</creatorcontrib><creatorcontrib>Bootsma, H.</creatorcontrib><creatorcontrib>Brouwer, E.</creatorcontrib><creatorcontrib>Spoorenberg, A.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maas, F.</au><au>Arends, S.</au><au>Wink, F.R.</au><au>van der Veer, E.</au><au>Bos, R.</au><au>Bootsma, H.</au><au>Brouwer, E.</au><au>Spoorenberg, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB0658 Influence of Known Risk Factors on Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Long-Term Treatment with TNF Inhibitors: Results from The Glas Cohort</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2016-06</date><risdate>2016</risdate><volume>75</volume><issue>Suppl 2</issue><spage>1129</spage><epage>1130</epage><pages>1129-1130</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundIn ankylosing spondylitis (AS), the most important prognostic factor for spinal radiographic progression is the presence of syndesmophytes at study entry. In addition, male gender, older age, longer symptom duration, smoking, HLA-B27 positivity, and increased inflammatory markers were found to be associated with radiographic progression in AS.1ObjectivesTo investigate the influence of known risk factors on spinal radiographic progression in AS patients receiving long-term treatment with TNF inhibitors.MethodsConsecutive patients from the GLAS cohort receiving TNF inhibitors with baseline and biannual spinal radiographs untill 6 years of follow-up were included. Radiographs were scored in chronological time order by two independent readers according to the mSASSS. Single linear imputation of radiographic data was used in case patients had missing data at one or more intermediate follow-up visits. The influence of the earlier mentioned risk factors for radiographic progression was investigated using univariable and multivariable generalized estimating equations (GEE). Subsequently, radiographic progression was modeled with different time functions (linear and non-linear) to provide the best fit for the data in patients with and without risk factors. A time function with p≤0.05 contributed significantly to the model and the estimated mean progression rates of the 2-year time intervals were calculated.ResultsEighty patients were included; 70% were male, 78% HLA-B27+, mean age was 41±10 years, median symptom duration 14 (IQR: 8–24) years, mean BASDAI 6.0±1.7, mean ASDAS 3.8±0.8, and mean mSASSS 8.7±13.3.During 6 years of follow-up, mean progression was 4.2±4.8 mSASSS units. GEE revealed that baseline syndesmophytes, gender, age, and symptom duration were significantly associated with radiographic damage over time. No significant associations were found for smoking, HLA-B27 status, and elevated CRP levels. The presence of baseline syndesmophytes was the only independent predictor for progression.Baseline mSASSS was highest in AS patients with baseline syndesmophytes, male gender, age ≥40 years, and symptom duration ≥10 years. In these patients, mSASSS progression followed a non-linear course showing a reduction in estimated progression rates over time (Table 1). Most patients with syndesmophytes also had one or more other risk factors (e.g. male gender and symptom duration ≥10 years). A linear course with low estimated progression rates was found in patients without these risk factors (Table 1).ConclusionsIn our cohort of AS patients receiving long-term treatment with TNF inhibitors in daily clinical practice, patients with known risk factors for radiographic progression (especially the presence of baseline syndesmophytes) showed the highest radiographic damage scores at baseline and the highest but reducing radiographic progression over time. In contrast, patients without these risk factors showed less baseline damage and low linear progression rates.ReferencesArends S, et al. Curr Opin Rheumatol. 2014;26:259–68.AcknowledgementThe GLAS cohort was supported by an unrestricted grant from Pfizer. Pfizer had no role in the design, conduct, interpretation, or publication of this study.Disclosure of InterestF. Maas: None declared, S. Arends Grant/research support from: Pfizer, F. Wink Consultant for: Abbvie, E. van der Veer: None declared, R. Bos Grant/research support from: Pfizer, H. Bootsma: None declared, E. Brouwer Grant/research support from: Pfizer, A. Spoorenberg Grant/research support from: Abbvie, Pfizer, UCB, Consultant for: Abbvie, Pfizer, MSD, UCB, Novartis</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1136/annrheumdis-2016-eular.3912</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.1129-1130
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1901859654
source BMJ Journals - NESLi2
title AB0658 Influence of Known Risk Factors on Spinal Radiographic Progression in Ankylosing Spondylitis Patients Receiving Long-Term Treatment with TNF Inhibitors: Results from The Glas Cohort
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T22%3A02%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB0658%E2%80%85Influence%20of%20Known%20Risk%20Factors%20on%20Spinal%20Radiographic%20Progression%20in%20Ankylosing%20Spondylitis%20Patients%20Receiving%20Long-Term%20Treatment%20with%20TNF%20Inhibitors:%20Results%20from%20The%20Glas%20Cohort&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Maas,%20F.&rft.date=2016-06&rft.volume=75&rft.issue=Suppl%202&rft.spage=1129&rft.epage=1130&rft.pages=1129-1130&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2016-eular.3912&rft_dat=%3Cproquest_cross%3E4322514469%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901859654&rft_id=info:pmid/&rfr_iscdi=true